Dysport
(AbobotulinumtoxinA)Phase 3Biologic
This medication is a neurotoxin injection that blocks nerve signals to reduce uncontrollable muscle tightening and spasms. It's used to treat conditions like cervical dystonia (severe neck muscle contractions), reduce wrinkles between the eyebrows, and relieve muscle stiffness in the arms and legs.[1] Dysport is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Dysport is one of 14 biologic programs targeting Bruxism. It is currently in Phase 3.
2
Indications
15
Total Trials
2
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
10 competitors in Bruxism
#DrugCompanyPhaseTrials
1Botox
RRevance Therapeutics, Inc.
Approved
Advil
KKenvue Brands
Approved
Paraflex
WWim Janssens
Approved
Dysport
GGalderma R&D
Phase 3
Botox
AbbViePreclinical
Pharmacotherapy
UUniversity of Pittsburgh
Preclinical
Opipramol
WWroclaw Medical University
Preclinical
Prabotulinumtoxina
UUniversity of Southern California
Preclinical
Gabapentine
AAssistance Publique - Hôpitaux de Paris
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Botulinum Toxin3 trials
Safety and Efficacy2 trials
Efficacy and Safety1 trial
7 more indications
Shoulder pain1 trial
Glabellar Lines1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AbobotulinumtoxinA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- GGalderma R&D